B-Type Natriuretic Peptide Levels in Obese Patients With Advanced Heart Failure
Tamara B. Horwich, MD,
Michele A. Hamilton, MD, FACC and
Gregg C. Fonarow, MD, FACC*
Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, Los Angeles, California
View larger version (13K):
[in a new window]
|
Figure 1 Box plots showing median circulating levels of B-type natriuretic peptide (BNP) in lean, overweight, and obese heart failure patients. The lines represent the median, the boxes represent the interquartile range, and the I bars represent the 5th and 95th percentiles. BMI = body mass index.
|
|
View larger version (19K):
[in a new window]
|
Figure 3 B-type natriuretic peptide (BNP) levels (median) in lean, overweight, and obese patients stratified by gender, diabetes (DM), and hypertension (HTN).
|
|
View larger version (19K):
[in a new window]
|
Figure 4 B-type natriuretic peptide (BNP) predicts New York Heart Association (NYHA) functional class (A) and pulmonary capillary wedge pressure (PCW) (B) independent of body mass index (BMI). Median BNP levels in subjects with NYHA functional class III versus IV (A) and high versus low PCW (B) are depicted.
|
|
View larger version (37K):
[in a new window]
|
Figure 5 (A) Receiver-operator curves for prediction of death or urgent heart transplantation at one-year follow-up in lean, overweight, and obese subgroups. Arrows indicate best cutoff B-type natriuretic peptide (BNP). (B) Survival curves using the receiver-operator curve-determined best cutoff BNP level for each category of body mass index. p values, log rank test. AUC = area under the curve.
|
|
|
1,000 pg/ml by body mass index (BMI). In parentheses: n = patients with BNP